Celgene expands cancer offering with US$9bn acquisition of Juno
Celgene has been on an acquisition spree of late as it looks to fill a revenue hole that will likely come when its blockbuster multiple myeloma drug loses its patent protection in 2022
Company
Celgene Corporation
NASDAQ:CELG
Celgene Corporation is an integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
44 stories · page 2 of 3
Bitcoin, Juno Therapeutics, Celgene, Adient, Boeing Co, Interactive Brokers - AFTER HOURS
The sell-off of Bitcoin continued yesterday while on the equity markets Juno Therapeutics shot up on M&A developments
Celgene to acquire privately-owned biotech peer Impact Biomedicines for up to US$7bn
Celgene is paying US$1.1bn in cash upfront for the San Diego-based company, plus an additional US$1.4bn depending on the receipt of US Food and Drug Administration milestone approvals
Investments and investor services
Stocks go gently into the Christmas break
Bitcoin hit an all-time high on Sunday, rising above US$19,500; it is now trading at US$12,553
Celgene plummets as it cuts near-term and long-term guidance
The New Jersey-headquartered group now expects diluted earnings per share to be between US$4.78 and US$5.19 in 2017
NCR lowers guidance after disappointing ATM orders in the third quarter
Also featured: CAI International, Daqo New Energy, NCR Corporation, Supervalu, Skechers USA Inc, Celgene Corporation and Atlassian Corporation
Celgene stock drops on drug development disappointment
Ahead of Friday’s open, Celgene shares were down 5.67% trading at US$128.25
US benchmarks mixed; big tech stocks weigh on Nasdaq Composite
The FANG stocks were out of favour and dragged the tech-heavy Nasdaq Composite into the red
Celgene says US FDA places holds on clinical trials for cancer checkpoint inhibitor being developed with AstraZeneca
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
US stocks hit record highs as Dow adds 300 points, but pharma sink
US stocks hit fresh record highs on Wednesday, with the S&P 500 marking its biggest single-day gains since the presidential elections, as investors largely shrugged off declines in health care stocks
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
Agios says adios to some investors as cash seen shrinking
Shares of Agios Pharmaceuticals lose 13% after the company reports disappointing full-year results and a sapped cash outlook
Wall Street reverses to loss after Greek protests
Wall Street swung to losses following reports of violent protests in Greece after keeping within a narrow range of gains for most of the session as Federal Reserve Chair Janet Yellen signalled the central bank remains on track to raise inte
U.S. stock-index futures struggle for direction ahead of Yellen speech, Greek debt vote
U.S. stock-index futures were little changed and investors awaited Federal Reserve Chair Janet Yellen’s testimony before Congress. Futures for the Dow Jones Industrial Average rose 0.1 percent to 17,976, while those for the S&P 50